Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease

PharmacoEconomics

Volumn 23, Issue 2, 2005, Pages 133-141

  Hay, Joel W ^a   Sterling, Kimberly L ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; RANITIDINE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DYSPEPSIA; FEMALE; HEALTH STATISTICS; HUMAN; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

AGED; CHOLESTEROL, HDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; GEMFIBROZIL; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROCETOFEN; RISK REDUCTION BEHAVIOR;

EID: 16244415511     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523020-00005     Document Type: Article

References (32)

1. Heart and stroke statistical update [online]. Available from URL: http//www.americanheart.org/statistics/coronary.html [Accessed 2003 Jul 5]
2. Castelli QP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. Ann Epidemiol 1992; 2: 23-8
3. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282 (24): 2340-6
4. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
5. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8
6. Kelley MD. Hypercholesterolemia: the cost of treatment in perspective. South Med J 1990; 83: 1421-5
7. Sarma S, Fifer SK. Gemfibrozil cost-benefit study targeting subgroups for effective hyperlipidaemia drug therapy. Drugs 1990; 40: 42-52
8. Bergemann R, Brandt A, Siegrist W. Cost-effectiveness study of a lipid lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson). Pharmacoeconomics 1999; 15: 47-74
9. Perreault S, Hamilton VH, Lavoie F, et al. A head to head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1996; 10: 787-94
10. Gold, M, Siegel J, Russell L, et al. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996
11. Nyman J, Martinson M, Nelson D, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: The Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med 2002 Jan 28; 162 (2): 177-82
12. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999; 15 (1): 47-74
13. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-8
14. US decennial life tables for 1989-91 [online]. Available from URL: http://www.cdc.gov/nchs/data/de89_1_4.pdf [Accessed 2004 Apr 18]
15. Prescription price checker [online]. Available from URL: http://www.drugstore.com/pharmacy/prices. [Accessed 2004 Apr 18]
16. US Department of Labor Bureau of Labor Statistics [online]. Available from URL: http://www.bls.gov. [Accessed 2004 Apr 18]
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
18. Wittels EH, Hay JW, Gotto AM. Medical costs of coronary artery disease in the United States. Am J Cardiol 1990; 65: 432-40
19. Smith CA, Melfi JA, Kesterson BJ, et al. Direct medical charges associated with myocardial infarction in patients with and without diabetes. Med Care 1999; 37 (4): As4-11
20. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998; 81: 1110-5
21. Anderson RN. United States life tables, 1998. Natl Vital Stat Rep 2001 Feb 7; 48 (18): 1-40
22. Hay JW. Economic modeling and sensitivity analysis. Value Health 1998; 1: 187-93
23. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
24. Hay J, Wittels E, Gotto A. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991 Apr 15; 67 (9): 789-96
25. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31
26. Graham JD, Corso PS, Morris JM, et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19: 125-52
27. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285 (19): 2486-97
28. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26 Suppl. 1: S83-6
29. LoFibra® (fenofibrate) prescribing information. Sellersville (PA): Gate Pharmaceuticals, 2003 May
30. Gemfibrozil prescribing information. Weston (FL): Apotex Corporation, 2001 Nov
31. Lopid® (gemfibrozil) prescribing information. New York (NY): Pfizer Pharmaceuticals Inc. 2003 Aug
32. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481-92